Das Atze T, Jeeninga Rienk E, Berkhout Ben
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection & Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
HIV Ther. 2010 May 1;4(3):361-369. doi: 10.2217/hiv.10.20.
Since its discovery some 25 years ago, much has been learned about HIV type 1 and the molecular details of its replication cycle. This insight has been used to develop lentiviral vector systems that have advantages over conventional retroviral vector systems. For safety reasons, the lentiviral vector systems are replication incompetent and the risk of generating a replication competent virus has been minimized. Nevertheless, there may be certain applications for replication competent HIV based vector systems, and we will review our activities in this particular field. This includes the generation of a conditionally replicating HIV 1 variant as a safe live attenuated virus vaccine, the construction of mini HIV variants as cancer selective viruses for virotherapy against leukemia, and the use of a conditionally live anti HIV gene therapy vector. Although safety concerns will undoubtedly remain for the use of replication competent HIV based vector systems, some of the results in cell culture systems are very promising and warrant further testing in appropriate animal models.
自大约25年前被发现以来,人们对1型艾滋病毒及其复制周期的分子细节已有了很多了解。这些见解已被用于开发慢病毒载体系统,该系统比传统逆转录病毒载体系统具有优势。出于安全考虑,慢病毒载体系统无复制能力,产生具有复制能力病毒的风险已降至最低。然而,具有复制能力的基于艾滋病毒的载体系统可能有某些应用,我们将回顾我们在这一特定领域的活动。这包括产生一种条件性复制的HIV-1变体作为安全的减毒活病毒疫苗,构建微型HIV变体作为用于抗白血病病毒治疗的癌症选择性病毒,以及使用一种条件性活的抗HIV基因治疗载体。尽管使用具有复制能力的基于艾滋病毒的载体系统无疑仍存在安全问题,但细胞培养系统中的一些结果非常有前景,值得在适当的动物模型中进一步测试。